Rutika J. Mehta, MD, MPH, discusses the current treatment paradigm in HER2-positive gastric cancer.
Rutika J. Mehta, MD, MPH
Advertisement
Articles by Rutika J. Mehta, MD, MPH
Rutika J. Mehta, MD, MPH, discusses the role of biomarkers in gastric cancer.
Rutika J. Mehta, MD, MPH, discusses how treatment has evolved in recent years for gastric and gastroesophageal junction cancers.
Advertisement
Latest Updated Articles
Dr. Mehta on the Current Treatment Paradigm in HER2-Positive Gastric CancerSeptember 8th 2020
Dr. Mehta on the Role of Biomarkers in Gastric CancerAugust 26th 2020
Advertisement
Advertisement
Trending on OncLive
1
FDA CTGTAC Votes in Favor of RP1/Nivolumab Data in Advanced Melanoma
2
FDA Grants Priority Review to Subcutaneous Amivantamab in Head and Neck Cancer
3
Dr Barot on the FDA Approval of Palbociclib/Trastuzumab ± Pertuzumab in HER2+ Breast Cancer
4
Dana-Farber Researchers Identify CDK8 as a Potential Therapeutic Target for Alveolar Rhabdomyosarcoma
5